Treatment | Page 320 of 465

Myeloma :: Addition of Thalidomide to Myeloma Therapies Enhances Clinical Activity

Pharmion Corporation (Nasdaq: PHRM) today announced new data presented from two studies of thalidomide in combination therapy, including updated results from the pivotal MM-003 study in first-line multiple myeloma, and results from a study examining the effect of the addition of thalidomide to a post-transplant regimen. The results of these studies were presented at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH) in Orlando, December 9-12, 2006).

Breast Cancer :: Restoring Tamoxifen Sensitivity in Resistant Breast Cancer

The widely used breast cancer drug tamoxifen (Nolvadex?), which can become less effective over time, might retain its full strength indefinitely if used along with a second drug, according to new research in mice conducted by investigators from the National Cancer Institute (NCI), part of the National Institutes of Health, and their partners. The results appear in the December 11, 2006, issue of Cancer Cell.

Multiple Sclerosis :: Tysabri treatment to Scots with multiple sclerosis (MS)

The MS Trust is dismayed by the SMC decision to deny this treatment to around 1,000 Scots living with rapidly deteriorating MS, by banning the drug Tysabri (natalizumab).

Leukemia :: SPRYCEL, dasatinib 100 MG Once A Day more effective in leukemia

Today, Bristol-Myers Squibb Company (NYSE: BMY) announced results from a randomized Phase III study showing that patients receiving SPRYCEL 100 mg once a day achieved similar cytogenetic responses at six months with considerably fewer hematologic and non-hematologic adverse events than patients receiving three other dosing schedules of SPRYCEL.

Kidney Cancer :: Avastin shows positive outcomes in patients with advanced kidney cancer

An interim analysis of a phase III study in advanced renal cell cancer has shown that Avastin significantly prolongs the time patients live without their disease progressing.

Egyptian Health Minister Opens AstraZeneca’s New $32M Manufacturing Plant near Cairo

Egyptian Health Minister Dr. Hatem Mostafa El-Gabaly today opened a new $32 million tablet factory built by AstraZeneca near Cairo ? the company?s first manufacturing investment in the Middle East. David Brennan, Chief Executive Officer of AstraZeneca, also attended the opening ceremony at the factory in 6th of October City.

Breast Cancer :: EVISTA for Reduction of Invasive Breast Cancer Risk in Postmenopausal Women

Eli Lilly and Company (NYSE: LLY) announced today that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration’s Division of Drug Oncology Products (DDOP) for EVISTA? (raloxifene HCl) for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for breast cancer.

Colorectal Cancer :: Xeloda meets primary endpoint in multinational Phase III advanced colorectal cancer study

Roche announced today that a large, international Phase III study (NO16967) of 627 previously treated patients with advanced colorectal cancer met its primary endpoint of progression-free survival.

Leukemia :: Tasigna achieved impressive response rates in chronic myeloid leukemia patients

New clinical data presented today demonstrated that Tasigna? (nilotinib) eliminated or significantly reduced the presence of blood cells containing a defective chromosome in approximately half of adult patients with a form of life-threatening leukemia who developed resistance or intolerance to treatment with Glivec? (imatinib).

Healthcare :: GlaxoSmithKline and EPIX Pharmaceuticals enter drug discovery and development alliance

GlaxoSmithKline (GSK) and EPIX Pharmaceuticals today announced a worldwide multi-target strategic collaboration to discover, develop and market novel medicines targeting four G-protein coupled receptors (GPCRs) for the treatment of a variety of diseases, including EPIX?s novel 5-HT4 partial agonist programme, PRX-03140, in early-stage clinical development for the treatment of Alzheimer?s disease. The alliance with GSK will be conducted through its Center of Excellence for External Drug Discovery (CEEDD).